HOME > LATEST
LATEST
-
ORGANIZATION Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
-
BUSINESS Chugai’s Hemlibra Successor Shows Promise in PI/II Study
February 10, 2026
-
BUSINESS Leqembi Subcutaneous Autoinjector Gets Priority Review in China
February 10, 2026
-
REGULATORY LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
-
COMMENTARY Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
February 9, 2026
-
REGULATORY MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
-
BUSINESS Leqembi Global Sales Hit 61.8 Billion Yen in April-December: Eisai
February 9, 2026
-
BUSINESS Marubeni Rolls Out Antibiotic Xenleta in China
February 9, 2026
-
ORGANIZATION Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
-
BUSINESS HLC, Mochida Set to Launch Japan PIII Trial of Umbilical Cord-Derived MSC
February 9, 2026
-
BUSINESS Japan Ethical Drug Sales Up 3.2% in December: Crecon
February 9, 2026
-
ORGANIZATION Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
February 6, 2026
-
BUSINESS Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
February 6, 2026
-
BUSINESS Ono Recalls Certain Opdivo Lots over Possible Metal Contamination
February 6, 2026
-
BUSINESS Eisai Snares Japan Commercial Rights to Henlius’ PD-1 Inhibitor
February 6, 2026
-
BUSINESS Takeda Rolls Out 31-Foot Containers for Drug Transport
February 6, 2026
-
BUSINESS Okajima to Take Helm of Asahi Kasei Pharma in April
February 6, 2026
-
BUSINESS PeptiDream Kicks Off PII for Radiotherapeutic Targeting Prostate Cancer
February 6, 2026
-
BUSINESS Daiichi Sankyo Starts PI/PII Trial of ADC DS3790 in Blood Cancers
February 6, 2026
-
BUSINESS Keytruda Extends Lead to 28 Months in January Drug Ranking: Encise
February 6, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
